Adverse Event Clinical Research
1.0.1 - STU1
Adverse Event Clinical Research
1.0.1 - STU1
This page is part of the Adverse Event Clinical Research (v1.0.1: STU 1) based on FHIR (HL7® FHIR® Standard) v5.0.0. This is the current published version in its permanent home (it will always be available at this URL). For a full list of available versions, see the Directory of published versions
| Page standards status: Informative |
Generated Narrative: MedicationAdministration
Resource MedicationAdministration "medication-administration-kadcyla"
status: completed
| Concept |
| KADCYLA (RxNorm#1371046) |
subject: Patient/patient-example-kaitlyn-b " BOUNCE"
occurence: 2020-04-01
performer
Actors
Reference Practitioner/practitioner-oncology-nurse-jane " NURSE"
request: MedicationRequest/medication-request-example-kadcyla
note: 3.6mg administered by continuous infusion. Patient tolerated infusion without side effects. (By Practitioner/practitioner-oncology-nurse-jane @2020-04-01)
| Route | Dose |
| Intravenous route (qualifier value) (SNOMED CT#47625008) | 3.6 mg (Details: UCUM code mg = 'mg') |
IG © 2020+ HL7 International / Biomedical Research and Regulation. Package hl7.fhir.uv.ae-research-ig#1.0.1 based on FHIR 5.0.0. Generated 2024-04-30
Links: Table of Contents |
QA Report
| Version History |
|
Propose a change